Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study
Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study
复制标题
DOI：
10.1136/jnnp.65.2.155
复制
发表时间：
1998-08-01
影响因子：
11
通讯作者：
Hattori, T
中科院分区：
文献类型：
--
作者：
Asahina, M;Suhara, T;Hattori, T
目的：评估进行性核上性麻痹和帕金森病患者脑中的毒蕈碱乙酰胆碱受体（mAChRs），方法采用正电子发射断层扫描（PET）和[C-11] N-甲基-4-哌啶基二苯乙酸酯（[C-11]N-methyl-4-piperidyl benzilate）检测进行性核上性麻痹和帕金森病患者的胆碱能系统和认知功能使用[C-11]NMPB测定7名进行性核上性麻痹患者、12名帕金森病患者和8名健康对照者脑中的mAChR。进行性核上性麻痹患者均为痴呆。帕金森病组包括11名非痴呆患者和1名痴呆患者。采用简易精神状态检查量表（MMSE）评定认知功能障碍的严重程度。采用改良威斯康星州卡片分类测验（WCST）评价帕金森病患者和正常对照者的额叶认知功能。结果：帕金森病患者额叶皮层的平均K-3值（mAChR结合指数）显著高于正常对照者（P
Objectives-To assess muscarinic acetylcholine receptors (mAChRs) in the brains of patients with progressive supranuclear palsy and Parkinson's disease, and to correlate the cholinergic system with cognitive function in progressive supranuclear palsy and Parkinson's disease.Methods-Positron emission tomography (PET) and [C-11]N-methyl-4-piperidyl benzilate ([C-11]NMPB) was used to measure mAChRs in the brain of seven patients with progressive supranuclear palsy, 12 patients with Parkinson's disease, and eight healthy controls. All of the patients with progressive supranuclear palsy were demented. The Parkinson's disease group consisted of 11 non-demented patients and one demented patient. The mini mental state examination (MMSE) was used to assess the severity of cognitive dysfunction in all of the subjects. The modified Wisconsin card sorting test (WCST) was used to evaluate frontal cognitive function in the non-demented patients with Parkinson's disease and controls.Results-The mean K-3 value, an index of mAChR binding, was significantly higher for the frontal cortex in the patients with Parkinson's disease than in the controls (p